Abbott and MSD Announce Strategic Partnership to Distribute Innovative Oral Anti-Diabetic Medicines in India

Abbott and MSD Pharmaceuticals (tradename of Merck & Co., Inc., Rahway, N.J., USA) are announcing a strategic collaboration through a distribution agreement for MSD's oral anti-diabetic medicine, Sitagliptin, its combination, Sitagliptin/Metformin, and the extended-release version in India. Under this agreement, Abbott will distribute this portfolio, leveraging its broad in-country footprint to continue to make these medicines available to people in India. MSD's Sitagliptin, its combination, and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR.
Sitagliptin is a DPP4i or Dipeptidyl Peptidase IV Inhibitor, used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity.
In India, at least 60 per cent of deaths are attributed to non-communicable diseases or NCDs. Amongst these, the leading causes are diabetes, cardiovascular conditions and cancer. The country has an estimated 101 million people with diabetes, and 136 million people who are pre-diabetic, and are at a higher risk of developing diabetes in the future.
'As the largest diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system,' said Ambati Venu, Vice President for Abbott in India. He further added, 'We offer a wide range of solutions to help people manage diabetes more effectively, including testing, continuous glucose monitoring, nutrition and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health.'
Rehan A. Khan, Managing Director, MSD India Region stated, 'Since its introduction in India over 17 years ago, our sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Indian Express

18 hours ago

• Indian Express

Scientists say they may have found a way to extend human lifespan

For decades, scientists have been trying to find a way to extend human lifespan, and while studies have shown that select lab animals can live longer by eating less, they haven't conducted these studies on humans. A century-old study on lab rats has shown that mice who eat less often outlive their fed counterparts, but it can be almost impossible for most humans to follow a permanent diet. However, a new study by the School of Biological Sciences, University of East Anglia, claims that a combination of FDA-approved drugs that mimic the effects of dieting might be the answer to a longer life. The two drugs – Rapamycin and Metformin are known to extend the lifespan of mice as much as up to 30 per cent. Rapamycin, which was first found in the 1970s in bacteria living on the Easter Island soil, has been traditionally used as a powerful immunosuppressant to prevent organ-transplant rejection. The drug works by disabling a particular switch which is used to inform cells when a cell has an abundance of nutrients. As for Metformin, it is a synthetic compound that is found in French Lilac or Goat's Rue, which doctors prescribe to control sugar levels in type 2 diabetes. Since both of these drugs are used to sense the nutrient and energy levels in the human body, biologists wanted to see if the combination of these drugs could have the same effect as eating less. To know more about their effects, scientists say they examined thousands of existing studies and came across 167 studies that focused on eight vertebrate species, like fish and monkeys, which offered them a detailed insight into how these drugs affected animals. Out of three strategies that help with longevity, eating less, taking Rapamycin and consuming Metformin, scientists say the most dependable way to increase the lifespan is to eat less, irrespective of the animal's sex. They also noted that the second most effective strategy to increase lifespan was to take Rapamycin, while Metformin had no substantial effect. However, scientists did say that the effect of Rapamycin on animals wasn't consistent, as, in some cases, studies have shown that eating less or taking Rapamycin reduced an animal's lifespan. Another thing to note here is that most of these positive effects were on mice and rats, which have genes similar to humans but are not exactly the same. And since Rapamycin does come with some side effects, like reduced immunity, scientists are now trying to see if lower doses of the drug offer some advantages without the side effects. According to an ongoing Rapamycin trial on humans, it was noted that lower doses of the drug might help increase the lifespan. But, as of now, the trial is still in progress and will take a few years before the results are out.

The Hindu

3 days ago

• The Hindu

Abbott to distribute MSD's diabetes drug in India

Abbott and MSD Pharmaceuticals have entered into a distribution agreement for MSD's oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version in India. Leveraging its broad footprint in the country Abbott will distribute the portfolio. The products are marketed under brand names Januvia, Janumet and Janumet XR, the companies said in a joint statement. Sitagliptin is a Dipeptidyl Peptidase IV Inhibitors used for treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity, they said. 'Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health,' V-P of Abbott in India Ambati Venu said. MSD India Region Managing Director Rehan A. Khan said, 'Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'

Business Standard

3 days ago

• Business Standard

Abbott, MSD join hands to distribute key diabetic drug across India

Two multinational drug makers—Abbott and MSD Pharmaceuticals—have announced a strategic collaboration to distribute the anti-diabetic medicine sitagliptin and its combinations in India. MSD's sitagliptin and its combinations are marketed in India under the brand names Januvia, Janumet, and Janumet XR. The two American pharmaceutical giants will join hands to leverage Abbott's extensive Indian footprint to distribute this widely used diabetes medication. Sitagliptin, a DPP4 inhibitor used to treat Type 2 diabetes, was launched by MSD in India in 2008. Following the patent expiry in mid-2022, several Indian drugmakers introduced generic versions of the molecule. The sitagliptin market in India is estimated to be worth ₹950–1,000 crore, forming a significant share of the country's ₹20,700 crore diabetes market. MSD said in a statement that its sitagliptin brands continue to be among the leaders in the segment, even after the loss of exclusivity. Before patent expiry, MSD had partnered with Sun Pharmaceutical Industries under a licensing agreement to distribute the drug in India. At that time, there were only four to five sitagliptin brands in the market, including Istavel and Istamet marketed by Sun Pharma. However, post-expiry, the market was flooded with over 150 brands from more than 60 pharmaceutical companies. MSD and Abbott's partnership aims to strengthen the reach of the innovator brands in a competitive market. In India, at least 60 per cent of deaths are attributed to non-communicable diseases (NCDs), with diabetes, cardiovascular conditions, and cancer being the leading causes. The country has an estimated 101 million people with diabetes and 136 million people who are pre-diabetic—at heightened risk of developing the disease in the future. 'As the largest diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system,' said Ambati Venu, vice-president, Abbott India. He added, 'We offer a wide range of solutions to help people manage diabetes more effectively—including testing, continuous glucose monitoring, nutrition, and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health.' Rehan A Khan, managing director, MSD India Region, stated, 'Since its introduction in India over 17 years ago, our sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. Our partnership with Abbott establishes a sustainable business model that will enable us to continue serving patients throughout India with these diabetes treatments.'